Author:
Ferrucci Michela,Fornai Francesco
Publisher
Springer International Publishing
Reference155 articles.
1. Algeri, S., Ambrosio, S., Garofalo, P., & Gerli, P. (1987). Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. European Journal of Pharmacology, 141(2), 309–312.
2. Alvarez-Fischer, D., Guerreiro, S., Hunot, S., Saurini, F., Marien, M., Sokoloff, P., Hirsch, E. C., Hartmann, A., & Michel, P. P. (2008). Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. Journal of Neurochemistry, 107(3), 701–711.
3. Anderson, G., Noorian, A. R., Taylor, G., Anitha, M., Bernhard, D., Srinivasan, S., & Greene, J. G. (2007). Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Experimental Neurology, 207(1), 4–12.
4. Andreassen, O. A., Ferrante, R. J., Dedeoglu, A., Albers, D. W., Klivenyi, P., Carlson, E. J., Epstein, C. J., & Beal, M. F. (2001). Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology, 167(1), 189–195.
5. Anglade, P., Vyas, S., Hirsch, E. C., & Agid, Y. (1997). Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histology and Histopathology, 12, 603–610.